Daily Aspirin Treatment After Preeclampsia
This study is looking at whether taking a daily low-dose aspirin (162mg) after experiencing preeclampsia can help prevent lasting blood vessel damage. Preeclampsia is a serious condition during pregnancy that can increase a woman's risk of heart disease later in life. Researchers want to see if aspirin can improve how your blood vessels work. You may be able to join if you are a woman between 18 and 50 years old and had preeclampsia within the last five years. The study will measure changes in your blood vessel function to see if aspirin is effective. The current status of this study is unclear.
- Study design
- This study is comparing daily aspirin (162mg) to a placebo (an inactive pill) in 40 women. It is an interventional study, meaning participants will receive a specific treatment.
- What's involved
- The study will measure your blood vessel function at the beginning and again after 12 weeks. Specific details about visits or other procedures are not provided.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 12 weeks after starting treatment to measure blood vessel function.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Daily Aspirin Treatment After Preeclampsia
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- magnitude of microvascular endothelial functionbaseline, 12 weeks
skin blood flow response to acetylcholine delivered via intradermal microdialysis
- magnitude of brachial artery endothelial functionbaseline, 12 weeks
brachial artery flow mediated dilation
- magnitude of microvascular endothelin-1 mediated constrictionbaseline, 12 weeks
skin blood flow response to endothelin-1 delivered via intradermal microdialysis